№60Brief2026-09-07

Moderna expands mRNA beyond personalized cancer vaccines

2 new development(s) in neoantigen vaccines today.

2new stories

CommercialtodayNew

Weekly Recap: Intismeran win and Personalis 13% stake backs Tempus AI - TradingView

Merck & Co., Inc. (NYSE:MRK) shares rose as positive trial results for the personalized cancer vaccine intismeran autogene—developed with Moderna—revived investor interest, while MRK’s 13% stake in Personalis and support for Tempus AI’s $1.5B sale at $16.25 tie strategic sequenci…

news · today · TradingView

Also new today01

ClinicalyesterdayNew

Moderna Expands mRNA Territory Beyond Personalized Cancer Vaccines to Universal Shots and In Vivo CAR-T - finance.biggo.com

Moderna is leveraging the Phase 3 success of its personalized mRNA cancer vaccine to expand its pipeline into universal cancer vaccines and in-body immune cell modification technologies. A common-antigen targeted therapy requiring no patient-specific manufacturing process, along …

news · yesterday · finance.biggo.com

Moderna expands mRNA beyond personalized cancer vaccines

Weekly Recap: Intismeran win and Personalis 13% stake backs Tempus AI - TradingView

Also new today01

Moderna Expands mRNA Territory Beyond Personalized Cancer Vaccines to Universal Shots and In Vivo CAR-T - finance.biggo.com

Explore the field